Question · asked by 1 review

5‐ASA vs purine antimetabolites: Serious adverse events

Population
people with surgically‐induced remission in Crohn's disease
Intervention
5‐ASA
Comparison
purine antimetabolites
Outcome
Serious adverse events

It is very uncertain whether 5‐ASA changes serious adverse events compared with purine antimetabolites (very low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
5‐ASA vs purine antimetabolites
Serious adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes serious adverse events compared with purine antimetabolites (very low certainty).
Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane Headline outcomes only
RR 0.3 [0.11, 0.8]3 studies · 311 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease
2019 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.